CRO Industry Pulse

John M. Hudak to be Featured Speaker at Airway Inflammation Drug Development Summit on December 4-5

The 2nd Annual Airway Inflammation Drug Development Summit will convene at The Sheraton National Hotel in Arlington, VA on December 4-5, 2006. It is hosted by The Center for Business Intelligence. This is designed to be a content rich scientific exchange for all aspects of the respiratory illness therapeutic area, including COPD (Chronic Obstructive Pulmonary Disease), Asthma, and Rhinitis.

On the first day of the Summit, John M. Hudak, President and Founder of Criterium, Inc. will deliver a Spotlight Session on the Subject of “Modern Perspectives for AGILE Clinical Trials in Airway Research — Cost and Time Savings for Sponsors Who Think Technology and Act Globally”, featuring actual case histories of airway inflammation research studies which benefited by utilizing real-time data analysis techniques that allowed for mid-study changes in strategy. This session will explore the many advantages to a sponsor when they choose to us technology-enhanced data collection methods. These advantages include cost savings, shortened study timelines, and earlier detection of study effects, both anticipated and unforeseen.

Colleagues and clients of Criterium, Inc. who are attending the conference are eligible for a $300 registration discount. Please click here for more information.

This conference will highlight the most current scientific advances and current status of therapeutic treatments for airway inflammation conditions, as well as discusses the extremely large market opportunity for therapeutics that address this important unmet medical need. Over 600 million people suffer from COPD and 3 Million die each year. The global market is over $2.8 billion currently to treat this disease. There remains a need to develop drugs that control the underlying inflammation and destructive processes that cause COPD. This disease has become the fastest growing health problem in the United States and is the 4th most common cause of death today and the only one in the top ten that continues to rise. Asthma affects 155 million worldwide. There has been a two-fold increase in the number of cases of asthma driving the market for pharmaceuticals up to nearly $8 billion. 15% of those patients suffer from uncontrollable disease symptoms increasing the need for novel therapies that possess new modes of action. For more information about the Airway Inflammation Drug Development Summit go to www.cbinet.com/airway.